Importantly, proteasome inhibitor MG132 treatment increased the total ZIP13 levels and restored the impaired intracellular zinc homeostasis of the SCD–EDS patient cells (Bin et al., 2014). The gene discussed is SLC39A13; the disease is Ehlers-Danlos syndrome.